Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
Launched by UNIVERSITEIT ANTWERPEN · Feb 21, 2019
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin treatment once a year compared to 2 and 3 times a year. All participants also receive anti-epileptic drugs according to local guidelines for epilepsy treatment. Participants will be followed for 12 months.The primary endpoint is seizure freedom defined as no seizures during the last fourth months of the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 5 years and above
- • Signed informed consent form
- • Normal neurological development until onset of epilepsy
- • Onset of epilepsy between ages of 5 and 18 years
- • Presence of microfilaria in skin snip and/or antibodies against Ov16
- Exclusion Criteria:
- • Ivermectin intake the last 9 months
- • Pregnancy or breastfeeding
- • Known or suspected allergy to Ivermectin
- • Loa Loa microfilariae in blood
- • Epilepsy with known cause (e.g. severe head trauma, perinatal asphyxia, patients with a history of cerebral malaria, meningitis or encephalitis)
- • Concomitant acute illness or chronic medication use
- • Chronic alcohol/substance use
About Universiteit Antwerpen
The University of Antwerp is a leading research institution based in Belgium, renowned for its commitment to advancing knowledge and innovation in various scientific fields. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials that aim to improve healthcare outcomes and enhance understanding of complex medical conditions. The University of Antwerp's dedicated research teams leverage cutting-edge methodologies and state-of-the-art facilities to conduct rigorous studies, ensuring adherence to the highest ethical standards and regulatory requirements. Through its clinical trial initiatives, the university strives to translate research findings into practical applications that benefit patients and contribute to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rethy, Ituri, Congo, The Democratic Republic Of The
Patients applied
Trial Officials
Robert Colebunders, MD,PhD
Principal Investigator
Universiteit Antwerpen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials